Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.60 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.60 |
| ▸ | HTR3B | O95264 | 4/20 | 0.60 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.60 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907742 | 1.00 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21730383 | 0.84 | CTSS (0.46) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21730194 | 0.84 | CTSS (0.46) | KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL29907703 | 0.84 | CTSS (0.46) | KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL2949577 | 0.83 | CTSS (0.45) | KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL2962315 | 0.82 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL27920871 | 0.81 | CTSS (0.44) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL15014503 | 0.81 | CTSS (0.50) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL21268766 | 0.80 | ALDH1A1 (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL2814727 | 0.80 | LRRK2 (0.52) | KDM4EALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023110843-A1 | HETEROBICYCLIC DERIVATIVES AS ITK INHIBITORS | ALMIRALL, S.A. (ES) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023099592-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-08 | — | — | WO | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-111747954-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111747954-A | Pyrazine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-10-09 | — | — | CN | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
| EP-2265600-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | Pfizer Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009098576-A1 | PYRIDINYL AMIDES FOR THE TREATMENT OF CNS AND METABOLIC DISORDERS | PFIZER INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | HTR3A 10/4885HTR3E 26/4885HTR3B 12/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | HTR3A 235/4885HTR3E 398/4885HTR3B 298/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | HTR3A 235/4885HTR3E 398/4885HTR3B 298/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | HTR3A 235/4885HTR3E 398/4885HTR3B 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.